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Abstract
Epidemiologists aim to inform the design of public
health interventions with evidence on the evolution,
emergence and spread of infectious diseases.
Sequencing of pathogen genomes, together with date,
location, clinical manifestation and other relevant data
about sample origins, can contribute to describing
nearly every aspect of transmission dynamics, including
local transmission and global spread. The analyses of
these data have implications for all levels of clinical and
public health practice, from institutional infection
control to policies for surveillance, prevention and
treatment. This review highlights the range of
epidemiological questions that can be addressed
from the combination of genome sequence and
traditional ‘line lists’ (tables of epidemiological data
where each line includes demographic and clinical
features of infected individuals). We identify opportunities
for these data to inform interventions that reduce
disease incidence and prevalence. By considering current
limitations of, and challenges to, interpreting these data,
we aim to outline a research agenda to accelerate
the genomics-driven transformation in public health
microbiology.
Introduction
Infectious disease epidemiologists study patterns of dis-
ease incidence, and seek ways to turn observations about
which individuals and populations become infected into
strategies to decrease the burden of disease. The effort
to identify predictors of who gets infected and who
among these becomes symptomatic requires first and
foremost the ability to define the disease. The advent of
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cheap, rapid whole-genome sequencing of pathogens is
the latest in a historic progression of the ways in which
epidemiologists classify disease; classification methods
have progressed from clinical and epidemiological defini-
tions of syndromes to microbiologic characterization of
pathogens from infected individuals (Figure 1), and now
to the use of pathogen genotype and genome sequence.
Improved characterizations of pathogens and deeper un-
derstanding of their biology have driven the develop-
ment of diagnostic techniques, vaccines and therapies,
and have helped guide strategies for maximizing the im-
pact of these tools for disease control and treatment. An
example of this progression can be seen in the study of
influenza, from the identification of influenza virus as
the etiologic agent [1,2], whereas formerly it was thought
to be bacterial [3], to the use of genetic and antigenic in-
formation to inform vaccine development [4,5], diagnos-
tics [6] and treatment selection [7]. Phylogeographic
analyses combine sequence and geographic data to make
inferences about the migration of influenza virus. Studies
of influenza A/H3N2 show that China and South-east
Asia are frequently the source of the lineages that then
circulate globally [8-10].
What does this new level of detail offer to the infec-
tious disease epidemiologist? Whereas the sequence of a
single organism or clone can address questions about
the microbe’s phenotype and history [11,12], compari-
sons of larger numbers of genome sequences can shed
light on evolution and population genetics, using little
other than the date of isolation in combination with se-
quence [13-16]. The combination of genome sequence
data from clinical and environmental isolates and epi-
demiological data about the sources of the isolates can
help characterize the origins, transmission, dynamics
and evolution of infectious disease epidemics, with exam-
ples ranging from understanding how the pneumococcal
population has evolved in response to use of antipneumo-
coccal vaccination in children [14] to the sources and
spread of the ongoing Ebola epidemic in West Africa [17].
In this review, we discuss the importance of these tools by
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gen genome sequences, then addressing the applications
of genomics-based methods for answering specific ques-
tions in infectious disease epidemiology and the associated
research questions and methodological constraints that
arise. Finally, we discuss policy and logistical and techno-
logical obstacles to achieving a potential transformation of
public health microbiology.
Conceptual advances in the use of pathogen
genomics for infectious disease epidemiology
Historically, epidemiological monitoring of infectious
diseases relied on case counts from clinical diagnosis,
and sought to turn data about the infected populations
into inferences about where and how the infectious dis-
ease spread. The most famous example is from the 19th
century, in which John Snow mapped the locations of
clinically defined cholera cases in an outbreak in London
and inferred that the outbreak was due to contaminated
water from the Broad Street pump; this was before iden-
tification of Vibrio cholerae as the etiologic agent. The
epidemiologist’s line list (Table 1) aims to capture critical
information about the demography, exposures and clin-
ical features of the infected individuals that can then in-
form hypotheses about the nature and dynamics of
disease transmission; for example, in the case of cholera
in 19th century London, the geographic location of cases
with respect to their water supply was used; however,
(a)
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Figure 1 Comparison of resolution of typing techniques. Typing methods range in resolution, from low resolution, which can classify isolates
as indistinguishable (I) from the index case (X), closely related (C, C1, and C2) or very different (D), to the high-resolution method of genome
sequencing, which can distinguish isolates by single nucleotide variation. Isolates indistinguishable by lower-resolution techniques may be
distinguishable by their sequences; indistinguishable by complete whole genome sequencing is by definition having the identical sequence.
(a-d) Schematic representations of pulsed-field gel electrophoresis (PFGE) (a), seroptying (using the example of serotypes of Streptococcus pneumoniae)
(b), multilocus sequence typing (MLST; in cartoon eBURST figure) (c), and a phylogeny from whole genome sequencing (d) show the different levels of
resolution. Whereas in PFGE, serotype and MLST, isolates can be identified as at coarse levels of relatedness, genotyping offers higher-resolution typing.
An isolate seen as closely related (C1) to the index case (X) in whole genome sequencing may be indistinguishable (I) in the first three methods,
whereas a more distantly related isolate, as seen by whole genome sequencing (C2), might appear as closely related. Moreover, as described in the text,
the integration of sequencing with molecular evolutionary theory provides much greater opportunity for phylogenetic inference, offering conceptual
leaps beyond other typing methods and greater contributions to infectious disease epidemiology.
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Demographic information Clinical data Diagnostic data Exposure data Microbial
sequence
a
Case identifier Age Gender Home location Presenting
symptoms
Date of onset Underlying medical
conditions
Clinical outcome Specimen type Diagnostic
test
Result Contacts
b Exposure
c
1
2
3
4
5
6
7
8
9
10
Line lists are used in epidemiological investigations. The data fields here are examples of the types of information collected from each case. The fields are adjusted on the basis of the specific disease or syndrome
under investigation. As sequencing of microbiological samples becomes part of routine clinical and public health microbiology practice, microbial sequence will become part of the line list data.
aLongitudinal time
points, deep-sequencing, single colony, multiple colonies, and so on;
bfor example, for communicable disease;
cfor example, foods eaten for food-borne outbreak.
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8more general characteristics, including age, gender and
date of diagnosis, are among features that can be used to
generate and test hypotheses about disease transmission
or population susceptibility.
Advances in diagnostic tools have led to a more re-
fined understanding of the dynamics of many infectious
diseases by typing the pathogens by a genetic or pheno-
typic feature and adding these data to the line list
(Table 2). Influenza again provides an illustrative ex-
ample. Whereas during the 1918 influenza pandemic,
the etiology of influenza was unknown (and mistakenly
attributed to Pfeiffer’s bacillus, now called Haemophilus
influenzae), we now have tools to confirm that an indi-
vidual’s infection is caused by influenza virus, and fur-
ther to characterize it by viral type, of which there are
two relevant to human disease, A and B, and by subtype,
defined by hemagglutinin (H) and neuraminidase (N),
with examples including A/H3N2, A/H1N1 and A/
H5N1. These data have clinical and epidemiological sig-
nificance. Clinically, they aid in guiding treatment and
prevention plans and in the development of novel diag-
nostics and therapeutics - for example, in 2009, recom-
mended antiviral treatment regimens varied depending
on whether an individual was infected with influenza A/
H1N1, influenza A/H3N2 or influenza B [7]. In the area
of prevention, development of effective vaccines depends
now on the identification of antigenic variants within
each subtype and construction of vaccines targeted to
these antigenic variants [18]. Epidemiologically, rather
than grouping all individuals with clinical influenza as
the same, these tools have aided in understanding the
evolutionary and epidemiological dynamics of influenza
lineages [8-10,19,20], as well as the different profiles of
mortality caused by each subtype [21]. Ironically, recent
efforts to create a universal influenza vaccine effective
against all subtypes may obviate some of the public
health need to track individual subtypes [22]. Yet, if suc-
cessful, the development of such vaccines will have
depended on extensive studies of vaccine immunogen-
icity and protective efficacy against defined serotypes.
Another phenotype that has been useful in monitor-
ing and responding to clinically important pathogens is
their pattern of susceptibility and resistance to a panel
of antibiotics, with examples including methicillin-resistant
Staphylococcus aureus (MRSA) and carbapenem-resistant
Enterobacteriaceae, each of which has been associated
with higher morbidity and mortality than drug-susceptible
strains [34-36]. Other phenotypic approaches, such as
serotyping, are shown in Box 1. Over the past several de-
cades, genotypic approaches have supplemented pheno-
typic approaches to microbial identification and typing
(Figure 1). In the 1990s, multilocus sequence typing
(MLST) [37,38] and various restriction-pattern based ap-
proaches such as pulsed-field gel electrophoresis (PFGE)
[39,40] and Southern-blot-based methods [41] defined
pathogen isolates by small segments of their genomes.
MLST, for example, helped to characterize the diversity of
Neisseria meningitidis, to confirm that meningococcal dis-
ease is caused by a small number of invasive lineages, and
to track these lineages as they spread geographically [38].
PFGE forms the basis of PulseNet [42], which uses this
tool to detect food-borne pathogen outbreaks, linking
Table 2 Time line of a number of key technological and scientific advances in infectious disease classification
Date Advance Applications
1670s Microscope invented by Leeuwenhoek Visualize bacteria, protozoa
1850s Puerperal fever identified as infectious and interventions
implemented by Semmelweis [23]
Hospital infection control motivated by growing understanding
of microbial etiology
1864 Cholera transmission by water proven by Snow Risk factor (mode of transmission) and prevention measure for
specific infectious syndrome
1890s Proof of parasitic origin (Grassi) and mosquito transmission
(Ross) of malaria
Vector control
1890s Identification of microbial etiologies for tuberculosis, anthrax,
and so on; Koch’s postulates
Targeted diagnostics, therapeutics, and move from syndromic
diagnosis to pathogen identification
1900-1930s Discovery of filterable animal viruses [24] Influenza etiology settled (previously thought bacterial) [25]
1910s-1950s Phenotypic subspecies taxonomy: serotyping [26,27],
phage typing [28]
Association of particular types with prognosis [27,29], drug resistance
1944 Discovery of DNA as the genetic material [30] Basis for genotyping tools for molecular epidemiology
1970 Restriction enzymes [31] Basis for restriction fragment length polymorphism approaches,
including pulsed field gel electrophoresis
1975-1985 Sanger DNA sequencing [32], PCR [33] Basis for variable number tandem repeat (VNTR) and multilocus
sequence typing (MLST) approaches to characterize microbes
and their genetic relatedness
2000s-now High-throughput rapid sequencing technologies Microbial genome sequencing
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otherwise have been seen as part of an outbreak (publica-
tions using PulseNet have been collated [43]).
Each of the approaches described above aims to use
characteristics of the microbial pathogens to better de-
fine the specific population responsible for a given out-
break, and thereby improve public health and clinical
responses. However, these approaches employ a fraction
of the data that could be used to resolve among isolates.
In particular, they can classify isolates as indistinguish-
able, closely related or very different, with only rough es-
timates of the rate at which such genotypic markers
diverge over time (Figure 1). Moreover, all of these
methods gain their signal from a small fraction of the
genome, so degree of similarity by these methods may
not reflect overall similarity of the genomes, especially in
pathogens that undergo frequent recombination, such that
genome segments may have varying histories [44,45]. For
this reason, direction and timing of evolutionary changes
were difficult to infer using older techniques, and detailed
phylogenetic inference was therefore impossible. As dis-
cussed below, many, though not all, of the advances pos-
sible with pathogen genomes build on the ability to infer
phylogenies from genome sequences.
Genome sequencing and statistical tools based on mo-
lecular evolutionary theory have led to conceptual leaps
over these prior typing schemes. Genome sequencing
enables discrimination of pathogen isolates at the single
nucleotide level, essentially providing a genome-level
typing tool that serves the same purposes as earlier typ-
ing tools, but with much higher resolution. However, the
biggest advances with pathogen genome sequences are
their application to address three broad sets of questions
that were difficult or impossible to answer with lower-
resolution molecular epidemiological tools that were
poorly suited to phylogenetic inference. First, analysis of
sequences from samples collected longitudinally and
from multiple sites over the course of an infection can
address the nature of variation and evolution within a
single infection, which occurs in bacterial, viral and
parasitic infections yet was often undetectable by earlier
typing methods [46]. Second, phylogenetic reconstruc-
tions from multiple pathogen genome sequences can be
used to infer the rates and routes of transmission
[47-49], providing information about the underlying
contact networks that led to these transmissions [50].
Whereas older methods could categorize pairs of isolates
as indistinguishable, closely related but distinguishable,
or distantly related, single-nucleotide polymorphisms be-
tween whole genome sequences provide a nearly con-
tinuous scale of distance between isolates that offers the
possibility of inferring the direction and routes of trans-
mission, while identifying changes associated with this
transmission history. Finally, sequence data can provide
much more detailed information on medium to long-
term microbial evolution, including variation in gene
content and evidence of selection under pressures from
interventions, such as vaccines, and changing niches
[14,44]. Moreover, the development of so-called phylo-
dynamic methods, largely based on coalescent theory
from population genetics, has shown that a set of se-
quences from one point in time contains information
about historical changes in the population size of the
pathogen, which aids inferences about the dynamics of
past transmission, that are independent of real-time case
counting [51,52].
These advances can help address the following key
questions that are of concern to the infectious disease
epidemiologist (see Box 2):
1. Is there an outbreak?
2. Where, when and how did a pathogen enter the
population of interest?
3. How quickly is the number of infections from the
pathogen growing (that is, what are the epidemic
dynamics)?
4. How is the pathogen spreading through the
population?
5. What genes or genotypes are associated with the
pathogen’s virulence or other phenotypes of interest?
In the sections below, we discuss the application of
genome sequencing to these questions. We reference se-
lect examples, when available, of how pathogen genom-
ics has been used to ask these questions. We note this
review is not an exhaustive catalog of pathogen genom-
ics efforts, as new and high-quality studies are being
Box 1. Techniques for classifying microbes for
epidemiological investigations
Phenotypic techniques
Biotyping (for example, biochemical reactions, colony
morphology)
Serotyping
Other typing tools (for example, bacteriophage, bacteriocin)
Antimicrobial susceptibility
Molecular/genomic techniques
Restriction fragment length polymorphism (for example,
pulsed-field gel electrophoresis)
Multilocus sequence typing
Genome sequencing
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trative examples. As the use of genomics, together with
traditional epidemiological data sources, raises not just
the conceptual advances described above, but also meth-
odological challenges and constraints, we also highlight
these challenges.
Application of genome sequencing to key questions
in the epidemiology of infectious diseases
Identifying outbreaks
The term ‘outbreak’ generally refers to an elevation in
disease incidence above background levels, and in more
specific cases the term can refer to the emergence of a
previously unrecognized pathogen such as Ebola in 1976
[53], HIV in the early 1980s [54,55], severe acute respira-
tory syndrome (SARS) in 2003 [56] or more recently
Middle East respiratory syndrome coronavirus (MERS-
CoV) [57]. The term can also refer to the initial entry of
a pathogen into a community, such as cholera, which
appeared in Haiti in 2010 [58,59]. Outbreaks are most
frequently caused by the transmission of a clonal lineage
of a pathogen, through a combination of limited initial
diversity and population bottlenecks in transmission.
Additionally, although rarely, outbreaks may also be
caused by multiple lineages or pathogens; these mixed
outbreaks may reflect co-circulating strains, such as in-
fluenza [60], a common source of contamination, such
as the salmonella and campylobacter outbreak [61], ‘epi-
demic plasmids’ [62], or common modes of transmission
[63]. Determining the presence of an outbreak, and whether
or not it is clonal, can then help direct the response to
abort it, as well as to prevent future outbreaks [64].
Several studies have used microbial genomics to deter-
mine whether a set of cases represents an outbreak by
determining the phylogenetic relationship among out-
break cases to determine their relationship; isolates that
are associated with a disease outbreak are often closely
related based on background population structure. Ex-
amples of such studies include identifying the clonality
of temporally and spatially linked hospital-based cases of
infections with MRSA [65], carbapenemase-producing
Enterobacter [66] and vancomycin-resistant enterococcus
[66]. A study of tuberculosis demonstrated the potential
utility in using genome sequencing to support both known
and unknown links among infected individuals in trans-
mission chains, and to help identify those likely not part
of an outbreak [67]. In a genome-sequencing-based study
of N. meningitidis from sporadic infections, epidemiologi-
cally unlinked cases were shown likely to be unrelated
(reflecting population diversity, rather than the clonality
expected from an outbreak) [66].
Interpretation of the phylogenetic relationships defined
by whole genome sequencing depends on understanding
the extent of diversity in the background population, the
population dynamics and amount of diversity within an
infected host, the population bottleneck in transmission
events, and the epidemiological findings associated with
each infection [64,66]. These background factors might
differ depending on features of the infectious disease,
including the mode of transmission (for example, contact-
based, respiratory, food-borne or vector-borne), the extent
Box 2. Using pathogen genomics in infectious disease
epidemiology
Pathogen genome sequencing can impact the study of
infectious diseases epidemiology through contributions to the
following questions:
Is there an outbreak?
When/where was the origin of the outbreak?
What is the growth rate and reproduction number?
What is the transmission chain (at the level of individuals or
populations)?
What genes and genotypes are associated with both pathogen
and clinical phenotypes of interest?
Addressing each of these questions, however, is not as simple
as just comparing the sequences of clinical isolates. Key areas of
both theoretical and experimental investigation that may be
needed to answer the questions and describe the confidence in
those answers include:
The microbial ecological diversity/population structure at the
appropriate scale for the outbreak question
The genomic diversity in a single infection, how dynamic this
diversity is over the course of an infection/colonization, and
how much of this diversity is transmitted
The extent of gaps in geographic and temporal sampling and
the potential of asymptomatic infection to contribute to
uncertainty
Uncertainty in phylogenetic models such as that deriving from
sampling biases and factors influencing determination of
molecular clock rate
Bringing these methods to public health microbiology
infrastructure poses its own set of challenges and opportunities.
These range from developing the databases and methods for
storing and analyzing line-list data that include pathogen gen-
ome sequences, determining the logistics of data sources and
sharing and interpretation and follow-up of results, and deter-
mining which agencies will fund the fundamental research that
will help this field grow as well as transition into a flexible and
modern system of public health microbiology.
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infection. As more studies investigate microbial popula-
tion structures and dynamics, as well as examining the
factors that influence them through experimental systems
and large-scale genomic and metagenomic clinical and en-
vironmental surveys, the ability to assess the confidence of
inferring epidemiological relationships based on genome
data will improve.
Determine the origin of an outbreak
The outbreak of a novel pathogen or the first entry of a
known pathogen into a location prompts questions
about its origin. The ability to pinpoint when and where
an outbreak began depends on how representative exist-
ing case reporting is, as well as on knowledge of the
population structure of the pathogen. In an ideal sce-
nario where all known cases are reported, determining
the origin of an outbreak is trivial. In reality, surveillance
systems and case reporting are incomplete. In these cir-
cumstances, the use of sample collection time-stamps,
where ‘time-stamp’ refers to the date when a sample was
collected, in reconstruction of the phylogeny can aid in
estimating the date of the most recent common ancestor
(MRCA) of the pathogens sampled from infected indi-
viduals, which must by definition be no older than the
origin of the outbreak. Additional demographic informa-
tion about the isolates, such as geographic location, can
contribute to estimating the characteristics of the MRCA
and improve understanding of the modes of spread of
the pathogen in question [68-73]; a recent study, for ex-
ample, uses such data to infer the roots of the HIV epi-
demic [73].
Phylogenetic inference addressing questions about the
origins of an outbreak requires background data that
scale with the desired resolution of the answer. When
the genome of V. cholerae from the outbreak in Haiti
was placed into a phylogenetic context, it was reported
that it was most closely related to a recently isolated
strain from South Asia [58,59]. The more densely sam-
pled the global population of the pathogen, both tem-
porally and geographically, the greater the confidence in
the inferences from the data. The availability of a larger
number of V. cholerae genomes from the outbreak in
Haiti, over several years [59], helped to improve the esti-
mation of the MRCA and support the epidemiological
hypothesis that there was a single introductory event
that took place in early autumn of 2010.
The ongoing Ebola crisis illustrates both the challenges
and promise of addressing questions about the origin of
an outbreak. Whereas genome sequences of the Ebola
virus from current and past outbreaks could be placed
into a phylogeny to guide inference about its appearance
for the first time in West Africa, the samples and the de-
tails of constructing the phylogeny can influence the
conclusions, such that differing phylogenies emerge from
inclusion and exclusion of intergenic regions [74,75].
Large-scale sequencing of patient samples can help con-
firm epidemiological conclusions that this outbreak had
a single origin [17]. The fact that only patient but not
environmental samples are available deepens the mystery
of the natural ecology of Ebola virus, and raises ques-
tions about the population structure of the environmen-
tal reservoir, and about the extent to which human
outbreaks are the products of rare exposure or rare
adaptation of Ebola virus to human hosts.
There are important caveats to the use of phylogenetic
models for inferring the origin(s) of a disease outbreak.
For example, the sensitivity of phylogeographic and phy-
lodemographic analyses remains unclear. As methods
develop to link phylogenetic reconstructions with geo-
graphic and demographic information, it is important to
be aware of the uncertainty in phylogenetic models. Re-
cent reviews discuss such methods and their utility in
epidemiological inference [52,76,77] and challenges in
their use [78].
A further caveat to the use of these data comes from
sampling biases and the risk of interpreting the resulting
phylogenies as if they are representative of an entire
pathogen population. Interpretation of phylogenies ben-
efits from characterizing the extent of asymptomatic in-
fection, which can influence the inference about the
epidemiological scenarios that gave rise to the outbreak;
the more unseen and unsampled transmitters, the more
difficult to accurately reconstruct transmission [79,80].
Gaps in geographic and temporal sampling will contribute
to uncertainty, suggesting that pathogens with extensive
asymptomatic and environmental or vector reservoirs
may face particular challenges that constrain the reso-
lution and confidence of phylogeny-derived estimates.
The greater the extent of uncharacterized disease and,
correspondingly, the greater duration of infection, rate of
diversification and transmitted diversity, the more uncer-
tainty in phylogeny-based inferences [81].
Calculate epidemic parameters
The epidemic growth rate and reproduction number (R)
are related measures of how contagious a pathogen is;
these measures guide risk assessment and interventions
for many infectious diseases, particularly emerging dis-
eases [82]. Formally, the reproduction number is the
number of cases on average caused by a single infected
individual over the course of the individual’s infectious
period, and the epidemic growth rate refers to the pro-
portional increase in the number of cases per unit time.
Gene genealogies have been used in estimating HIV’s
generation time [83], and the basic reproductive number
of hepatitis C virus (HCV) [84]. For infections whose in-
cidence and prevalence are difficult to observe directly
Grad and Lipsitch Genome Biology 2014, 15:538 Page 7 of 14
http://genomebiology.com/2014/15/11/538due to high fraction of asymptomatic, subclinical or un-
reported infection, inferences based on pure sequence
data may be usable to infer the effects of mass vaccin-
ation in reducing transmission [85].
In the early phase of an outbreak, when case detection
may be highly imperfect and nonrandom, molecular clock
estimates of time to the most recent common ancestor
can estimate the growth rate of the pathogen population
in a way that is partially independent of methods that rely
on ongoing case-ascertainment. Within months of the
emergence of the influenza strain pH1N1 in 2009, analysis
of the phylogeny using an evolutionary model with expo-
nential growth provided an estimate of the growth rate,
and, together with the assumption that pH1N1 had the
same generation time as other influenza infections, the re-
productive number [86]. Phylogenetic analysis can also
provide qualitative insights into epidemic parameters:
early analysis of MERS-CoV has offered an initial glimpse
of the pandemic potential of this pathogen, with interpret-
ation of clade disappearances as possibly reflecting an R0
less than 1 [80] (where R0 is the ‘basic reproductive num-
ber’, referring to the average number of infected individ-
uals caused by a single infectious person in an entirely
susceptible population). A feature of these approaches is
that they do not require (and in some cases cannot even
use) dense sampling of most cases from an outbreak, only
representative sampling of a fraction of cases at one or
more time points.
Integration of epidemiological models and phylogen-
etic reconstructions to infer epidemic parameters, in-
cluding R0, transmission rates and population size, is an
exciting and active area of research [52,87-89]. Although
work to date has focused on using these tools with rap-
idly mutating RNA viruses, including HIV, HCV and
dengue, development of statistical approaches that con-
sider the relationship between parameters such as the
serial interval (the average time between infection and
subsequent transmission), duration of infection, and
sampling of the lineages in an individual and the within-
host diversity, among others, will be needed to explore
generalizing these approaches.
Track and reconstruct transmission routes
Understanding transmission routes is essential in the con-
trol of infectious diseases. Studies that reveal who infected
whom can help to identify a pathogen’s mode of transmis-
sion and thereby direct infection control and prevention
policies to prevent further disease spread [65,90,91]. At
broad temporal or spatial resolution, tracking transmis-
sion can identify clusters of related cases and reveal pat-
terns of pathogen spread; this allows inferences about the
structure of the underlying network along which a patho-
gen spreads [92]. Accumulated experience from the study
of multiple outbreaks can then help understand the
common patterns for particular pathogens or populations;
as the transmission patterns for more outbreaks are de-
scribed, commonalities - for example, the extent to which
superspreaders are important - may help lead to more ef-
fective public health interventions.
A range of approaches recently developed to recon-
struct transmission at a detailed level involve statistical
analyses that formally combine evidence of genomic re-
latedness between pathogens isolated from different
hosts, with temporal, geographic and other data to arrive
at inference of likely transmission trees. In one innova-
tive example, spatial and temporal data were combined
with genomic data to estimate the spread of H7N7 influ-
enza among farms in the Netherlands, and then a mete-
orologic data set was overlaid to test the hypothesis that
wind direction explained patterns of spread [49]. Results
were consistent with this hypothesis, illustrating two
general points: first that genomic data can contribute to
identifying a new transmission mechanism, which in this
case was wind-borne transmission of influenza, and sec-
ond that as our understanding of transmission mecha-
nisms grows, the appropriate metadata to combine with
our analyses will also grow and be pathogen-specific in
some cases. Some of these approaches, particularly those
that wish to reconstruct individual transmission events,
require dense sampling of most of the cases in an out-
break, and can be complicated by factors that limit or
bias sampling, including undetected unknown or diffi-
cult to access reservoirs, including asymptomatic and
vector-borne infections. Other approaches, which focus
on less granular inference, such as transmission from
one sexual mixing group or city to another, without
interest in the individual involved, can be applied to
much sparser samples. Importantly, recent work has also
emphasized the limits of inference of transmission from
genomic data alone and indicated that it can both help
motivate and substantiate traditional epidemiological ef-
forts and conclusions [48,93].
Identify genes and genotypes associated with pathogen
phenotypes of interest
Traditionally, surveillance has been a largely separate activ-
ity from functional genetic analysis of pathogens. As se-
quence data become more fully integrated into surveillance,
it becomes natural to ask how far the functional and
phenotypic interpretation of such data can be pushed, from
identifying putative virulence factors by the presence or ab-
sence of a gene [94] to performing genome-wide associ-
ation studies (GWAS) using large numbers of isolates [95].
For the epidemiologist, this also provides genetic signatures
of specific phenotypes - such as resistance or virulence -
that can be tracked in the context of routine surveillance,
monitoring of strains and development of new diagnostics.
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resistance phenotypes, have to be collected alongside
sequence data to assemble the database from which
correlations between genotype and phenotype can be
observed. Classical genetic studies can then test hy-
potheses about which of these observed correlations are
causal. Those that are suggest the opportunity to de-
velop new diagnostic and prognostic tests based on se-
quence data alone and to suggest further hypotheses
about pathogen biology and host-pathogen interactions
that can direct additional experiments.
This approach has three requirements. First, it requires
standardized and reproducible genomic assemblies and an-
notations or access to the raw reads for each of the isolates
so that uniform tools can be applied to analyze genotype-
phenotype relationships. Second, it requires reporting of
the key phenotypic data, including clinical data, for micro-
bial GWAS to search for pathogen determinants of clinical
manifestations. For optimal scientific and public health
outcomes, such data should be stored in standardized fash-
ion and should be available for study, regardless of whether
the original analyses are done by individual institutions
with ‘in-house’ sequencing and bioinformatics expertise or
through ‘send-out’ testing to companies that report geno-
type and phenotype information. Third, the use of geno-
type to replace culture and phenotypic testing requires
caution, given that linkage, epistasis and other processes
may weaken the strength of the genotype-phenotype asso-
ciation over time. The emergence and spread of a Chla-
mydia trachomatis variant in Sweden characterized by
a deletion in the locus targeted by a commonly used
nucleic acid amplification diagnostic test offers one related
cautionary tale [96]. Even in the context of an experimen-
tally established causal genotype-phenotype relationship,
repeated validation over time will be required as, for ex-
ample, alternative genetic bases for the phenotype may ap-
pear in the population.
Whereas many properties of an infection may be pre-
dictable from pathogen genotype alone, assessment of
change in pathogen populations in response to large-
scale interventions, such as pneumococcal vaccination,
provides an opportunity to monitor the ecological response
of microbial communities and the interplay between hosts
and pathogens [14]. Studies of niche differentiation suggest
a key new direction for understanding and modeling infec-
tious disease transmission, building on prior work that uses
serotypes to consider the heterogeneity in which pathogens
infect which people. To date, heterogeneity is mostly
considered in terms of acquired immunity or proxies
for it, such as age. Studies such as the age-stratification
of pneumococcal gene content [14] suggest signatures
of interplay between host immunity and pathogen evo-
lution. Vaccine escape is one of the most important mani-
festations of these interactions; deepening characterization
of the immune responses of hosts in which escape mu-
tants arise and transmit most successfully offers a particu-
larly exciting and developing field [97]. This is particularly
high risk/reward as many hypotheses may be wrong, but
so far we have modeled spread of particular species largely
without regard to heterogeneity of which pathogen infects
which person.
Implementation of microbial genomics in public
health: challenges and opportunities
Individual studies that demonstrate the potential for
pathogen genome sequences to contribute to infectious
disease epidemiology and public health make a compel-
ling case for incorporating these data into standard prac-
tice; however, the implementation presents a number of
challenges and opportunities.
Database and analytical development
As databases grow in sequence and metadata, and ideally
incorporate the dates and locations of sample collec-
tions, as well as the method of isolation of the se-
quenced samples from the environment or infected
individual, rapid integration of new data may permit au-
tomated identification of outbreaks and inferences about
their origins. A system that recognizes the appearance of
samples more closely related than expected based on
what is known about the population structure and inci-
dence could accelerate outbreak identification and facili-
tate responses. Further, by maintaining a database of
samples that describe the ecology of a pathogen and the
background population diversity, it may also be easier to
place a clinical specimen into a phylogeny to infer its
origin and identify the existence of an outbreak. For ex-
ample, the time taken to discover an outbreak spread
across locations, such as a food-borne outbreak in which
the contaminated items are shipped to a broad geo-
graphic area, could be improved [98]. Incorporation of
sequence data in routine disease surveillance could help
shed light on the transmission dynamics of pathogens,
and thereby guide public health interventions. The Glo-
bal Microbial Identifier project [99] and similar efforts
aim to address the challenges of generating a uniform
database of microbial sequences and associated meta-
data, though the technical and political obstacles to uni-
versal uptake are formidable.
The role of microbial genomics in public health and
clinical microbiology raises critical questions about in-
frastructure development and training personnel who
bridge understanding of the subtleties of the infectious
diseases they study with familiarity with genomics and
bioinformatics techniques. Laboratories interested in de-
veloping their own sequencing platform will have to in-
vest in one of the available technologies, and, as of now,
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and interfacing with public databases. This will require
some combination of hiring bioinformaticians and pro-
viding training to clinical microbiology and public health
laboratory staff. Similarly, infectious disease epidemiolo-
gists who will be asked to incorporate genomic data into
their routine practice will need background in genomics
and associated methods and theory as well as skills in
processing and managing these data sets. Further, as the
field is rapidly evolving technologically and computa-
tionally, the creation of ‘gold standard’ approaches for
clinical and public health practice will likely need fre-
quent updating.
Data sources
What sets of data should be included in these databases?
Infectious disease epidemiological studies draw on rou-
tine surveillance projects, outbreak investigations, and
research studies. The addition of pathogen genome se-
quences is a natural extension to these studies that helps
achieve their goals. Another potential source of data
comes from the clinical microbiology laboratories that,
for the most part, do not publish or make available data
on the types and numbers of microbes identified from
patients. With clinical microbiology laboratories taking
up microbial genome sequencing [100], there are re-
markable and potentially transformative opportunities
for vastly expanding the data streams available for un-
derstanding infectious disease dynamics and microbial
ecology and evolution, including the emergence and
spread of antimicrobial resistance. As the technology
and tools for bringing pathogen genome sequencing into
clinical realms develops, it is worth following the models
of efforts to monitor antibiotic resistance (for example,
WHONET [101], EARS-Net [102]) for specific or,
ideally, for all clinically isolated pathogens and exploring
ways to include and automate uploading these data to
public health microbiology databases.
The potential contributions from such a vast expan-
sion of available public health and microbiological data
make it important to consider the associated questions.
If sequencing of clinical samples becomes a routine part
of clinical care or local infection control, should there be
an obligation for clinical laboratories to upload their
data (stored in a wide range of electronic medical re-
cords systems) to a uniform public health database?
What data, and for what pathogens? If sequencing is not
part of routine clinical care or local infection control,
then what pathogens should be sequenced, by whom
and with what funding? Will the growing consortium of
public health agencies, academics and industry recom-
mend standardized sequencing and analytic methods
to facilitate integration of data from across multiple
institutions? If so, whose job should it be to generate
and maintain the standards in this rapidly developing
field? There will be false positives for any algorithm that
is intended to detect outbreaks; what false-positive rate
will be acceptable? Who will have the responsibility for
following up possible outbreaks? Failure to include clin-
ical microbiological samples and data, and failure to de-
velop standards that allow for temporal and geographic
aggregation of data, will represent a huge missed oppor-
tunity for advancing infectious disease epidemiology and
public health.
Privacy and legal concerns
A critical question in the integration of genomics into
public health microbiology is to understand what extent
data should be available to researchers and the public.
This has institutional and infrastructure implications for
how the metadata that accompany the microbial genome
sequences should be collected and stored. Ideally, metadata,
including microbiological phenotype profiles of antibiotic
resistance, and patient-centered data on host demograph-
ics and clinical course, would be readily accessible for au-
tomated analyses or for directed research investigations.
However, it is worth noting that collection, storage and
use of patient-centered data raises privacy and security is-
sues that will need to be addressed. This also raises
medical-legal scenarios, depending on availability of data
and on confidence in the conclusions: when is action to
investigate a potential outbreak warranted, and when is it
obligatory?
Funding
As described above, there are many emerging research
questions related to transforming public health micro-
biology through the use of genome sequencing and
analysis. Traditionally, genome sequencing and other
sophisticated laboratory-based technologies have been
the province of funding bodies and research groups de-
voted to basic biomedical science, while the detection
and characterization of outbreaks, along with routine
surveillance, have been the province of epidemiologists
and others specializing in applied public health. In the
application of a now established technology to answer
questions at the population level, cooperation between
these groups is essential, both to ensure that a promis-
ing transdisciplinary approach does not fall through
the cracks between funders with priorities on one side
or the other of the basic biology-epidemiology divide,
and to ensure that the best technology is married with
the best quantitative and analytical tools at stages from
study design and data collection through analysis and
inference.
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To date, studies as described above have demonstrated
the potential for an expanded line list of data that include
genome sequences to augment epidemiological inquiry
and generate inferences about the spread and evolution of
pathogens, to help guide efforts to reduce disease burden.
Recent incorporation of pathogen genome sequencing
into the efforts of Public Health England [103] and em-
phasis on the importance of a public health surveillance
and response system based on pathogen genomics in
the recent report from the President’sC o u n c i lo fA d v i -
sors on Science and Technology in September 2014 on
combating antibiotic resistance [104] foreshadow the
large-scale adoption of pathogen genomics into the public
health infrastructure. Maximizing impact will require basic
and applied research efforts to develop the methods, data-
bases, analytics and platforms to go from samples to action-
able public health data, and the creation of a flexible
system that can test and incorporate novel epidemiological
approaches.
For most pathogens, there are fundamental aspects of
microbial diversity in human hosts and the environ-
ment that we do not yet understand but which bear dir-
ectly on epidemiological questions. Foundational work
is needed at many levels, including: description of gen-
etic diversity over the course of an infection and in
transmission, first under ‘typical’ conditions and, over
time, with a more sophisticated understanding of the
impact of other factors on this diversity, such as micro-
biome, immunocompromised status, duration of infection,
route of transmission, level of symptomatic disease and
other host characteristics [105]; defining the population
structure of pathogens at multiple geographic, demo-
graphic and temporal scales; methodological advances in
phylogenetic approaches that can integrate within-host
and population diversity into statistical measures of confi-
dence in reconstructions of transmission chains, and ap-
proaches to dealing with the impact of missing data on
phylogenetic reconstructions and epidemiological infer-
ence. Advances in these fields, and in fields that study
heterogeneity in host susceptibility, suggest exciting di-
rections for improving public health efforts for infec-
tious disease treatment and prevention.
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